EGFR and non-small cell lung carcinoma: Remarkably, the EGFR-positive disease may be considered the paradigm of oncogene-addicted NSCLC, for which the AF detected at baseline or during targeted therapy represents a clear predictor of response and survival outcomes [11,12].